Association of British Clinical Diabetologists

IDegLira Nationwide Audit

 
Home Live ABCD audits of new therapies and devices All ABCD nationwide audits Future audits of new therapies ABCD worldwide audits
     

Above - in clinical trials, HbA1c reduction was considerably more for IDegLira compared to insulin glargine used in a treat to target algorithm. The audit may give insight into whether this advantage translates into real clinical practice - click to enlarge

 

Above - in clinical trials, body weight increased with insulin glargine used in a treat to target algorithm, whereas with IDegLira body weight decreased. The audit may give insight into whether this advantage translates into real clinical practice - click to enlarge

 

Above - in clinical trials, there was much less confirmed hypoglycaemia and nocturnal confirmed hypoglycaemia for IDegLira compared to insulin glargine used in a treat to target algorithm. The audit may give insight into whether this advantage translates into real clinical practice - click to enlarge

 

ABCD nationwide IDegLira audit

About the ABCD nationwide IDegLira audit
This audit follows on from the success of the previous ABCD nationwide audits of GLP1 receptor agonists, SGLT2 inhibitors, and insulin degludec. The clinical trials of IDegLira seem to show in those uncontrolled on basal insulin (20-50units), IDegLira showed statistically improved HbA1c reductions in comparison to the up titration of insulin glargine U100 with fewer hypoglycamic episodes and less weight gain, and indeed with weight loss - see slides on the left for examples of the data concerned. Also in clinical trials, when iDegLira was compared to liragutide in patients uncontrolled on OADs or to unchanged maximum tolerated GLP-1 (liraglutide or exanetide bd) results showed statistically improved HbA1c and FPG control with fewer gastrointestinal side effects but higher rates of hypoglycaemia and less weight reduction in one trial and weight increase in another. We hope through this nationwide audit to find out if these findings from the clinical trials translate into the same advantages when the agent is used in real clinical practice. The audit will be hosted on a tool very similar to that used in the liraglutide audit and the degludec audit so the many contributors taking part in those audits will find it particularly easy. The audit will launch in February or March, 2017, and has a number of objectives.

Collect data on-line or via paper forms
The IDegLira on-line audit tool is so easy to use that live data entry in clinic is a real option to be considered. Otherwise to facilitate data collection during clinics there are two paper forms which exactly match the data that can be entered into the audit tool. You can download and print these forms locally or
order pre-printed data entry forms.

To download the forms to printout for use, use the following links:

Download first visit data entry form
Download follow up visit data entry form

Non ABCD members
Non ABCD members are welcome to take part in the audit and will be given access to the on-line audit tool when they register for the audit.

Register to take part in the audit and access to the on-line tool
To register for the audit and be given access to the on-line tool click here.

Further information
Further enquiries may be made to the ABCD nationwide audits database administrator of the project, Jayne Starrett

   Register for the audit

Access the on-line tool

IDeglira audit objectives

Order preprinted data entry forms

Download first visit data entry form

Download follow up visit data entry form

Further information- contact us

Main ABCD homepage

     

The ABCD nationwide IDegLira audit is an independent audit supported by an unrestricted grant from Novo Nordisk

Working to support high quality diabetes care in the UK